1. Home
  2. MDGL vs GGB Comparison

MDGL vs GGB Comparison

Compare MDGL & GGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • GGB
  • Stock Information
  • Founded
  • MDGL 2011
  • GGB 1901
  • Country
  • MDGL United States
  • GGB Brazil
  • Employees
  • MDGL N/A
  • GGB N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • GGB Steel/Iron Ore
  • Sector
  • MDGL Health Care
  • GGB Industrials
  • Exchange
  • MDGL Nasdaq
  • GGB Nasdaq
  • Market Cap
  • MDGL 6.1B
  • GGB 5.7B
  • IPO Year
  • MDGL N/A
  • GGB 1999
  • Fundamental
  • Price
  • MDGL $414.68
  • GGB $2.98
  • Analyst Decision
  • MDGL Strong Buy
  • GGB Strong Buy
  • Analyst Count
  • MDGL 8
  • GGB 1
  • Target Price
  • MDGL $445.71
  • GGB $3.80
  • AVG Volume (30 Days)
  • MDGL 469.6K
  • GGB 9.4M
  • Earning Date
  • MDGL 08-05-2025
  • GGB 07-31-2025
  • Dividend Yield
  • MDGL N/A
  • GGB 3.35%
  • EPS Growth
  • MDGL N/A
  • GGB N/A
  • EPS
  • MDGL N/A
  • GGB 0.29
  • Revenue
  • MDGL $515,547,000.00
  • GGB $12,681,996,398.00
  • Revenue This Year
  • MDGL $286.67
  • GGB $7.48
  • Revenue Next Year
  • MDGL $67.98
  • GGB $5.59
  • P/E Ratio
  • MDGL N/A
  • GGB $9.72
  • Revenue Growth
  • MDGL 3421.98
  • GGB 6.96
  • 52 Week Low
  • MDGL $200.63
  • GGB $2.27
  • 52 Week High
  • MDGL $419.99
  • GGB $3.62
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 77.54
  • GGB 51.95
  • Support Level
  • MDGL $351.32
  • GGB $2.85
  • Resistance Level
  • MDGL $393.76
  • GGB $2.97
  • Average True Range (ATR)
  • MDGL 17.32
  • GGB 0.07
  • MACD
  • MDGL 6.15
  • GGB -0.00
  • Stochastic Oscillator
  • MDGL 94.95
  • GGB 61.90

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About GGB Gerdau S.A.

Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment.

Share on Social Networks: